Format

Send to

Choose Destination
Drug Discov Today. 2008 Jan;13(1-2):38-43. doi: 10.1016/j.drudis.2007.10.007. Epub 2007 Nov 26.

Development and application of Hsp90 inhibitors.

Author information

1
Department of Medicine and the Human Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, United States.

Abstract

Heat shock protein 90 has emerged as an important target in several diseases. The present review will discuss our understanding of the role played by Hsp90 in regulating and maintaining the transformed phenotype in cancers and neurodegenerative diseases, as well as recent findings on its roles in fungal and viral infections. It will also update the reader on the preclinical development and clinical translation of Hsp90 inhibitors.

PMID:
18190862
DOI:
10.1016/j.drudis.2007.10.007
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center